Top

Gepubliceerd in:

2009 | OriginalPaper | Hoofdstuk

12 Niet-alcoholische steatohepatitis

Auteur : Prof.dr. P.L.M. Jansen

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Epidemiologisch onderzoek heeft aangetoond dat leversteatose een onschuldige aandoening is die vanzelf overgaat of met een paar eenvoudige aanpassingen van de levensstijl volledig reversibel is. Zo laat een longitudinaal populatieonderzoek in Noord-Italië zien dat een met echografie geconstateerde steatose 8,5 jaar later bij de meeste mensen volledig verdwenen was.

vorige hoofdstuk 11 Auto-immuunhepatitis en overlapsyndromen

volgende hoofdstuk 13 Alcoholische leverziekte

Bedogni G, Miglioli L, Masutti F et al. Incidence and natural course of fatty liver in the general population:the Dionysos study. Hepatology 2007;46(5):1387–1391.PubMedCrossRef

Ekstedt M, Franzen LE, Mathiesen UL, et al. Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865–873.PubMedCrossRef

Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123(1):134–140.PubMedCrossRef

Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37(1):154–160.PubMedCrossRef

Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;128(5):837–847.PubMedCrossRef

Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006;26(9):1021–1028.PubMedCrossRef

Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94(4):1018–1022.PubMedCrossRef

Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356–1362.PubMedCrossRef

Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36(1):142–149.PubMedCrossRef

10.

Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Nonalcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31(3):421–429.PubMedCrossRef

11.

Nelson JE, Bhattacharya R, Lindor KD, et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007;46(3):723–729.PubMedCrossRef

12.

Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123(3):745–750.PubMedCrossRef

13.

Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288(2):E462–E468.PubMedCrossRef

14.

Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (Fibro- Test, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 2007;25(2): 207–208.PubMedCrossRef

15.

Poynard T, Morra R, Halfon P, et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7(1):40.PubMedCentralPubMedCrossRef

16.

Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.PubMedCentralPubMedCrossRef

17.

Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004;40(2):475–483.PubMedCrossRef

18.

Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007;133(1):80–90.PubMedCrossRef

19.

Roskams T, Yang SQ, Koteish A, et al. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol 2003;163(4):1301–1311.PubMedCentralPubMedCrossRef

20.

Yang S, Koteish A, Lin H, et al. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 2004;39(2):403–411.PubMedCrossRef

21.

Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38(4):999–1007.PubMedCrossRef

22.

Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002;35(4):898–904.PubMedCrossRef

23.

Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002;282(2):G193–G199.PubMedCrossRef

24.

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796–1808.PubMedCentralPubMedCrossRef

25.

Fliers E, Romijn JA, Sauerwein HP, Kalsbeek A, Kreier F, Buijs RM. [Vetweefsel: een geïnnerveerde endocriene klier]. Ned Tijdschr Geneeskd 2002;146(42):1976–1979.PubMed

26.

Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423(6941):762–769.PubMedCrossRef

27.

Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8(11):1288–1295.PubMedCrossRef

28.

Kim JY, van de Wall E, Laplante M, et al. Obesityassociated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007;117(9): 2621–2637.PubMedCentralPubMedCrossRef

29.

Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004;53(2):123–129.PubMed

30.

Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48(2):206–211.PubMedCentralPubMedCrossRef

31.

Ide T, Shimano H, Yahagi N, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 2004;6(4):351–357.PubMedCrossRef

32.

Bellentani S, Dalle GR, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008;47(2):746–754.PubMedCrossRef

33.

Toshimitsu K, Matsuura B, Ohkubo I et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007;23(1):46–52.PubMedCrossRef

34.

Cortez-Pinto H, Jesus L, Barros H, Lopes C,Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006; 25(5):816–823.PubMedCrossRef

35.

Wang J, Ueda N. Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens 2008;17(1):1–10.PubMedCrossRef

36.

Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 2007;27(8):1152–1155.PubMedCrossRef

37.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370(9600):1706–1713.PubMedCrossRef

38.

Baltasar A, Serra C, Perez N, Bou R, Bengochea M. Clinical hepatic impairment after the duodenal switch. Obes Surg 2004;14(1):77–83.PubMedCrossRef

39.

Castillo J, Fabrega E, Escalante CF, et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001;11(5):640–642.PubMedCrossRef

40.

Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPARgamma ligand rosiglitazone. Hepatology 2003;38(4): 1008–1017.PubMedCrossRef

41.

Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1):188–196.PubMedCrossRef

42.

Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46(2):424–429.PubMedCrossRef

43.

Angelico F, Burattin M, Alessandri C, Del BM, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007;1:CD005166.PubMed

44.

Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47(4):565–570.PubMedCrossRef

45.

Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007;357(1):28–38.PubMedCrossRef

46.

Henriksen JH, Ring-Larsen H. Rosiglitazone: Possible complications and treatment of non-alcoholic steatohepatitis (NASH). J Hepatol 2008;48(1):174–176.PubMedCrossRef

47.

Menon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am J Gastroenterol 2001;96(5):1631–1634.PubMedCrossRef

48.

Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6(9):998–1003.PubMedCrossRef

49.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358(9285):893–894.PubMedCrossRef

50.

Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53(8):2169–2176.PubMedCrossRef

51.

Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31(2):384.PubMedCrossRef

52.

Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double- blind randomized controlled study. J Hepatol 2003;38(4):414–418.PubMedCrossRef

53.

Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98(11):2485–2490.PubMedCrossRef

54.

Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39(3):770–778.PubMedCrossRef

55.

Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99(5):1408–1413.PubMed

56.

Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27(1):103–107.PubMedCrossRef

57.

Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56(12):1760–1769.PubMedCentralPubMedCrossRef

58.

Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98(4): 926–930.PubMedCrossRef

59.

Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20(6):623–628.PubMedCrossRef

60.

Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136(6):734–738.PubMedCrossRef

61.

Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38(5):681–687.PubMedCrossRef

62.

Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholinduced steatohepatitis: a pilot study. Hepatology 1996;23(6):1464–1467.PubMedCrossRef

63.

Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996; 403:607–613.PubMedCrossRef

64.

Abdelmalek.MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96(9):2711–2717.PubMedCrossRef

Titel: 12 Niet-alcoholische steatohepatitis
Auteur: Prof.dr. P.L.M. Jansen
Uitgeverij: Bohn Stafleu van Loghum
Boek: Leverziekten
Print ISBN: 978-90-313-7436-6

Elektronisch ISBN: 978-90-313-7437-3

Copyright: 2009
DOI: https://doi.org/10.1007/978-90-313-7437-3_12

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen